Southpoint Capital Advisors Lp Sells 1,000,000 Shares of Fennec Pharmaceuticals (TSE:FRX) Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) insider Southpoint Capital Advisors Lp sold 1,000,000 shares of the company’s stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of C$10.35, for a total value of C$10,350,000.00. Following the completion of the sale, the insider directly owned 2,744,741 shares in the company, valued at approximately C$28,408,069.35. The trade was a 26.70% decrease in their ownership of the stock.

Southpoint Capital Advisors Lp also recently made the following trade(s):

• On Friday, November 14th, Southpoint Capital Advisors Lp sold 160,100 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$11.24, for a total value of C$1,799,524.00.
• On Monday, November 17th, Southpoint Capital Advisors Lp sold 85,918 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$12.35, for a total transaction of C$1,061,087.30.

Fennec Pharmaceuticals Price Performance

Shares of Fennec Pharmaceuticals stock opened at C$10.46 on Monday. Fennec Pharmaceuticals Inc. has a 1 year low of C$7.02 and a 1 year high of C$13.83. The firm has a market cap of C$357.24 million, a price-to-earnings ratio of -40.23 and a beta of 2.78. The company has a 50-day moving average of C$10.75 and a 200 day moving average of C$11.55. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.